Study to evaluate the effectiveness and saftyof the mFOLFOX+bevacizumab combination therapy for bladder adenocarcinoma
Not Applicable
- Conditions
- bladder adenocarcinoma
- Registration Number
- JPRN-UMIN000021193
- Lead Sponsor
- agoya City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
Not provided
Exclusion Criteria
1.Case with serious myelosuppression 2.Case with the diarrhea (stools watery) 3.Case who had a serious infection 4.A large quantity of ascitic fluid, case with the pleural effusion 5.Case with serious heart disease or the anamnesis 6.The case that overall status worsens 7.Case with severe dysesthesia with the functional disorder or the dysesthesia 8.A pregnant woman or the case that may be pregnant and nursing mother 9.It is a case with a history of hypersensitivity for an ingredient including, levofolinate, fluorouracil, oxaliplatin and other platinum
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method